Search

Displaying results 5531 - 5540 of 10000 in total
  1. Drug

    Asoprisnil

    go.drugbank.com/drugs/DB06680
    Investigational

    Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.

  2. Drug

    Adakitug

    go.drugbank.com/drugs/DB05484
    Investigational

    MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation.

  3. Drug

    Amediplase

    go.drugbank.com/drugs/DB06679
    Experimental

    Amediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.

  4. Drug

    Gemcabene

    go.drugbank.com/drugs/DB05123
    Investigational

    Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).

  5. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

  6. Drug

    Pegargiminase

    go.drugbank.com/drugs/DB06592
    Investigational

    Pegargiminase is an anticancer agent.

  7. Drug

    Thiazinam

    go.drugbank.com/drugs/DB13420
    Experimental

    Categories: Antihistamines for Systemic Use
  8. Drug

    Tacalcitol

    go.drugbank.com/drugs/DB13689
    Investigational

    Categories: Antipsoriatics for Topical Use
  9. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  10. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO.